Trial Profile
A Phase 2 Study of Atengenal (A-10) and Astugenal (AS2-1) in Diffuse, Intrinsic Pontine Glioma (DIPG)
Status:
Suspended
Phase of Trial:
Phase II
Latest Information Update: 14 Mar 2023
Price :
$35
*
At a glance
- Drugs Antineoplaston A10/antineoplaston AS2-1 (Primary)
- Indications Diffuse intrinsic pontine glioma; Glioma
- Focus Therapeutic Use
- Acronyms DIPG
- Sponsors Burzynski Research Institute
- 21 Feb 2022 Planned End Date changed from 1 Mar 2022 to 1 Mar 2028.
- 21 Feb 2022 Planned primary completion date changed from 1 Mar 2022 to 1 Mar 2028.
- 21 Feb 2022 Planned initiation date changed from 1 Apr 2016 to 1 Apr 2024.